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Abstract 
 
Background To deliver efficacious personalised cancer treatment, it is essential to characterise the cellular 
metabolism as well as the genetic stability of individual tumours. In this study, we describe a new axis between 
DNA repair and detoxification of aldehyde derivatives with important implications for patient prognosis and 
treatment. 
Methods Western blot and qPCR analyses were performed in relevant non-transformed and cancer cell lines from 
lung and liver tissue origin in combination with bioinformatics data mining of The Cancer Genome Atlas database 
from lung and hepatocellular cancer patients. 
Results Using both biochemical and bioinformatics approaches, we revealed an association between the levels of 
expression of the aldehyde detoxifying enzyme aldehyde dehydrogenase 2 (ALDH2) and the key DNA base 
excision repair protein XRCC1. Across cancer types, we found that if one of the corresponding genes exhibits a 
low expression level, the level of the other gene is increased. Surprisingly, we found that low ALDH2 expression 
levels associated with high XRCC1 expression levels are indicative for a poor overall survival, particularly in 
lung and liver cancer patients. In addition, we show that Mithramycin A, a XRCC1 expression inhibitor, efficiently 
kills cancer cells expressing low levels of ALDH2. 
Conclusions This study suggests that lung and liver cancers require efficient single-strand break repair for their 
growth in order to benefit from a low aldehyde detoxification metabolism. We also propose that the ratio of 
XRCC1 and ALDH2 levels might be a useful prognosis tool in these cancer types.   
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1 Introduction 
 
Aldehydes are abundant organic molecules that can be assimilated from food or produced within cells as by-
products of cellular metabolism. Among many cellular aldehydes, acetaldehyde (AcAl) is the most studied, 
particularly for its importance in cancer metabolism [1-3]. Endogenous AcAl is mainly produced by the cellular 
processing of alcohol and also as an intermediate in sugar metabolism [4]. Aldehydes are highly reactive 
molecules, generating a range of DNA modification products including DNA strand crosslinks and DNA-protein 
crosslinks [4]. Due to their toxicity, AcAls are processed in human cells by detoxification enzymes such as 
aldehyde dehydrogenase 2 (ALDH2), which oxidises AcAl to acetate [5]. Until recently, very little was known 
about how cells respond to DNA damage induced by AcAls. New studies suggest that AcAl-induced DNA damage 
is likely to be processed by multiple DNA repair pathways due to its complexity [6-9]. Two DNA repair pathways 
involved in repair of DNA crosslinks and DNA double strand breaks have been implicated in repair of AcAl-
induced DNA damage thus far [6]. However, in addition to DNA strand crosslinks and DNA-protein crosslinks, 
AcAls also generate multiple DNA base modifications and neither of these pathways can deal with base 
modifications. N2-ethylidenedeoxyguanosine is the main adduct, and its reduced form N2-ethyldeoxyguanosine 
[10] has been directly linked to ALDH2, since its levels increase in ALDH2 knockout mice treated with ethanol 
[11]. 
Base excision repair (BER) is the primary mechanism responsible for repairing most endogenous DNA 
lesions, including numerous types of damage to nitrogenous bases that can be induced by AcAls [12]. BER is a 
well understood DNA repair pathway [13, 14]. It is initiated by a DNA glycosylase that recognizes the damaged 
DNA base and cleaves the N-glycosylic bond that binds the DNA base to the sugar-phosphate backbone. A new 
site without a base residue (also called an abasic site, an AP site or an apurinic/apyrimidinic site) is further 
processed by an AP endonuclease (APE1 in human cells) that cleaves the phosphodiester bond next to the AP 
site, thereby generating a DNA strand break containing a hydroxyl residue at the 3'-terminal and deoxyribose 
phosphate at the 5'-end. Further, DNA polymerase β, using its AP-lyase activity, removes deoxyribose phosphate 
from the 5'-end and simultaneously adds one nucleotide to the 3'-end of the nick. DNA repair is completed by 
sealing the ends by the complex of two proteins, XRCC1 and DNA ligase IIIα [12]. XRCC1 is a scaffold protein 
that is essential for the formation and stabilization of the ternary DNA polymerase β-XRCC1-DNA Ligase IIIα 
complex that is necessary to complete BER [15]. Hence, cells deficient in XRCC1 are characterized by reduced 
DNA repair and increased genomic instability (reviewed in [16]). 
We previously showed that loss of BER triggers metabolic changes, notably by increasing the activity of 
the one-carbon cycle [17], which endogenously produces and metabolises formaldehyde, an even more reactive 
molecule than AcAl [2]. If BER-deficient cells increase the activity of this cycle, it is reasonable to suggest that 
this would in turn increase the concentration of formaldehyde in cells as both a waste product and a reaction 
intermediate. We thus hypothesised that BER-deficient cells may have increased levels of aldehydes. As a result, 
these cells would be in need of increasing an aldehyde detoxification system, such as ALDH2, to counteract AcAl 
and formaldehyde toxicity. Here, we tested this hypothesis along with its potential consequences on cancer 
aggressiveness and prognosis. 
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2 Materials and methods 
 
2.1 Cell cultures and drug 
The non-transformed bronchial epithelium cell line LIMM-NBE1 has previously been described in [18]. The 
normal human fibroblast cell lines TIG-1 and WI38 were obtained from the Coriell Institute Cell Repository. The 
non-small cell lung carcinoma-derived cell line H1299 was obtained from the American Type Culture Collection 
(ATCC), while the liver carcinoma-derived cell line JHH4 was kindly provided by Prof Ricky Sharma (University 
College London). All cell lines were cultured in DMEM (Life Technologies) supplemented with either 15% FBS 
(for the LIMM-NBE1 cell line) or 10% FBS (for the cancer cell lines) at 37°C in a humidified atmosphere with 
5% CO2. Cells were routinely checked for mycoplasma. Mithramycin A was purchased from Enzo Life Sciences. 
 
2.2 siRNA transfection 
siRNA transfections were carried out using the Lipofectamine RNAiMAX reagent (Life Technologies) according 
to the manufacturer’s protocol. Unless otherwise indicated, cells were transfected with 30 nM siRNA and analysed 
72 hours after transfection. siRNA oligonucleotides were obtained from Eurogentec. Sequences were as follows:  
XRCC1 5'-AGGGAAGAGGAAGUUGGAU-3', TDP1 5'-GACCAUAUCUAGUAGUGAU-3' and ALDH2 5'-
CCUCAAAUGUCUCCGGUAU-3'. Control transfections were carried out using a non-targeting siRNA 
(Eurogentec, SR-CL000-005), referred to as NC. 
 
2.3 Western blotting 
Whole cell extracts for Western blotting were prepared as described previously [19]. The antibodies used were 
directed against XRCC1 (MS-1393-P0, Neomarkers), ALDH2 (102-10056, Cambridge Biosciences), β-actin 
(ab6276, Abcam) and α-Tubulin (T6199, Sigma Aldricht). Detection and quantification was carried out using an 
Odyssey image analysis system (Li-Cor Biosciences). 
 
2.4 DNA-protein crosslink isolation and quantification 
LIMM-NBE1 cells were grown to 100% confluency in 10-cm dishes in order to synchronise them in G1 phase, 
as XRCC1 siRNA stops the cell cycle in this cell line. DNA-protein crosslinks (DPCs) were detected using a 
modified rapid approach to the DNA adduct recovery assay [20]. In brief, 1.5 to 2 x 106 cells were lysed in 1 ml 
M buffer (MB) containing 6 M Guanidine Thiocyanate, 10 mM Tris–HCl (pH 6.8), 20 mM EDTA, 4% Triton 
X100, 1% Sarkosyl and 1% Dithiothreitol. DNA was precipitated by adding 1 ml 100% ethanol and washed three 
times in wash buffer (20 mM Tris–HCl pH 6.8, 150 mM NaCl and 50% ethanol) after which DNA was solubilized 
in 1 ml 8 mM NaOH. A small aliquot of the recovered DNA was digested with 50 μg/ml proteinase K (Invitrogen) 
for 3 hours at 50°C and quantified using PicoGreen dye (Invitrogen) according to the manufacturer’s instructions. 
The DNA concentration was further confirmed by slot-blot analysis followed by immunodetection with an 
antibody directed against dsDNA. To quantify DPCs, DNA was digested with benzonase (Invitrogen) for 30 
minutes at 37°C, after which proteins were precipitated by the standard Trichloroacetic Acid protocol [21], 
dissolved in Laemmli buffer, resolved by SDS-PAGE gel and visualized by silver staining. 
 
2.5 Immunofluorescence assay 
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Immunofluorescence was carried out following standard procedures. Briefly, cells were fixed with 
paraformaldehyde (4% in PBS for 15 minutes). Permeabilisation was carried out using Triton X-100 (0.2% in 
PBS for 10 minutes at 4°C) after which cells were saturated with 5% bovine serum albumin (BSA) in PBS for 1 
hour. Subsequent incubation with an anti-ALDH2 antibody (102-10056, Cambridge Biosciences) was carried out 
in 5% BSA-PBS supplemented with 0.01% Tween 20. Alexa Fluor 594-conjugated secondary antibodies (Life 
Technologies) were used for indirect detection of the antigens. Hoechst 33342 (Life Technologies) was used to 
visualise nuclei. Images were taken by confocal microscopy using a Zeiss LSM 710 microscope. 
 
2.6 Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted using a RNeasy kit (Qiagen) and cDNA was prepared using a SuperScript RT-PCR 
system (Life Technologies) as per manufacturer’s instructions. qRT-PCR was performed using a Fast SYBR® 
Green Master Mix (Applied Biosystems) according to the manufacturer’s protocol. Reactions were carried out 
using a 7500 Fast Real-Time PCR System (Applied Biosystems). The comparative CT method was applied for 
quantification of gene expression; GAPDH and B2M were used as endogenous controls, unless otherwise stated. 
The following Primers were used:  
ALDH2 (For: CCTCTCCAGTGGACGGATT; Rev: CGAGGTCTTCTGCAACCAG) 
GAPDH (For: AGCCACATCGCTCAGACAC; Rev: GCCCAATACGACCAAATCC) 
B2M (For: ATGTCTCGCTCCGTGGCCTTA; Rev: ATCTTGGGCTGTGACAAAGTC) 
TBP (For: CGGTTTGCTGCGGTAATCAT; Rev: TTTCTTGCTGCCAGTCTGGAC) 
XRCC1 (For: CTGGGACCGGGTCAAAAT; Rev: CAAGCCAAAGGGGGAGTC) 
APE1 (For: CGGACAAGGAAGGGTACAGT; Rev: CAAATTCAGCCACAATCACC) 
TDP1 (For: CGCTTGTTTCTTCAGCTCAG; Rev: ACAAGCAGGATTGGCTTCTT) 
 
2.7 Clonogenic assay 
500 cells were seeded per well in 6-well plates, with three technical replicates of each variable. In Figures 8D and 
E, siRNA transfections were carried out 24 hours before seeding. In Figure 9A, cells were allowed to attach for 
at least 18 hours before Sp1 inhibitor addition, at the indicated concentrations. Sp1 inhibitor was added for 48 
total hours, replenishing the inhibitor at 24 hours. Surviving cells were allowed to proliferate for 10–14 days. 
Cells were fixed for 30 minutes in 0.4% methylene blue dye in methanol. Only colonies of more than 50 cells 
were counted using the automated system GelCount™ by Oxford Optronix. Each graph represents the mean of at 
least 3 independent experiments. 
 
2.8 Bioinformatics analyses 
Bioinformatics analyses were performed using publicly available data from the Oncomine® (www.oncomine.org), 
cBioPortal (http://www.cbioportal.org) [22, 23] and TCGA (RNAseq data) (cancergenome.nih.gov) databases. 
Studies using the Oncomine® database can be found in Table S1. All data extracted from cBioPortal (Coming 
originally from TCGA) can be found in Table S2 (Lung cancer [NSCLC]), Table S3 (Liver cancer) and Table S4 
(Esophageal cancer). 
 
2.9 Statistical analyses 
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Statistical analyses were performed by the two-tailed Student’s t-test using either Microsoft Excel or SPSS (IBM). 
 
 
3 Results 
 
3.1 ALDH2 expression is increased following BER deficiency 
We previously showed that BER-deficient cells adjust their metabolism to prevent oxidative stress by producing 
anti-oxidant molecules such as GSH [17]. We hypothesised that BER-deficient cells operate in a similar way to 
prevent aldehyde-induced DNA damage by enhancing detoxification systems. To test this, we downregulated 
BER in the non-transformed cell line LIMM-NBE1 (hereafter NBE1) by reducing the expression of the key BER 
protein XRCC1, using siRNA. We observed a significant increase in ALDH2 expression both at the mRNA (Fig. 
1A) and protein (Fig. 1B) level 72 hours after siRNA treatment. The localisation of ALDH2, as shown by 
immunofluorescence, was unchanged and the increase corresponds to a cytoplasmic localisation (Fig. 1C). The 
increase in ALDH2 expression following XRCC1 depletion was also observed in two additional normal human 
fibroblast cell lines TIG1 (Fig. 1D) and WI38 (Fig. 1E). APE1, POLβ and XRCC1 are the essential components 
of BER. However, APE1 has diverse cellular functions and its depletion is highly toxic, creating many types of 
lesions, ranging from apurinic/apyrimidinic AP-sites to double-strand breaks [24, 25]. POLβ knockout cells are 
BER deficient, but to a lesser extent than XRCC1 knockout cells [26]. We therefore considered XRCC1 
knockdown as the optimal model of BER deficiency [17]. Nevertheless, it is also possible to simulate BER 
deficiency by creating unresolved single-strand breaks (SSBs) through the depletion of BER end processor protein 
tyrosyl-DNA phosphodiesterase 1 (TDP1), which catalyses the removal of Type I topoisomerase blocked at the 
3-prime phosphate end of the DNA single- strand break [17]. Doing so, we again observed an increase in ALDH2 
expression (Fig. 1F). This would suggest that it is the accumulation of SSBs that triggers ALDH2 up-regulation. 
Next, we investigated whether this balancing mechanism was linked to the detoxification of aldehydes and their 
products, DNA-protein crosslinks (DPCs [27]). Despite an increased amount of ALDH2, we observed a slight but 
significant increase in DPCs in XRCC1-deficient cells compared to control cells treated with unspecific siRNA 
(Fig. 1G, compare lanes 1 and 2). This might suggest that even with more ALDH2, DPCs are still occurring more 
frequently in BER-deficient cells. In positive control experiments, inhibition of aldehyde detoxification by the 
pan-ALDH inhibitor Disulfiram lead to substantial DPC accumulation in NBE1 cells (Fig. 1G, lane 3), confirming 
that ALDH2 detoxification activity can prevent DPC formation. From these results, we conclude that BER-
deficient cells accumulate SSBs that might directly or indirectly, by increasing, for example, the amount of 
reactive aldehydes [26], provoke an increase in DPCs. In response, cells increase ALDH2 expression, potentially 
in order to prevent further accumulation of DPCs. 
 
3.2 ALDH2 expression is low in most cancers whereas XRCC1 expression is high 
DPCs are a major threat to DNA replication and genomic stability. Accumulation of DPCs has been observed 
during aging, neurodegeneration and cancer development [28]. In order to understand why cancer cells are unable 
to prevent the induction of DPCs and other DNA damage, caused by the accumulation of reactive aldehydes, we 
carried out bioinformatics analysis of ALDH2 mRNA levels in different cancer types using the Oncomine® 
database (Fig. 2). Strikingly, we noticed that, when ALDH2 mRNA expression is significantly deregulated, it is 
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for a major part by downregulation (Fig. 2A and 2B). We found that the levels of ALDH2 mRNA are particularly 
low in melanoma, sarcoma, leukaemia and bladder cancer (Fig. 2A). It is also important to emphasize that ALDH2 
mRNA is expressed at its highest levels in tissues such as the liver, brain and lungs [29]. All of these tissues, when 
cancerous, showed lower ALDH2 mRNA levels (Fig. 2A). Interestingly, we found that the levels of XRCC1 
mRNA expression seem to generally reverse ALDH2 mRNA expression levels by being higher in most cancerous 
tissues (Fig. 2A and 2B). This is more obvious in sarcoma and bladder cancer, but more interestingly in liver, 
brain and lung cancers (Fig. 2A). Globally at the median value, we found that ALDH2 is downregulated by more 
than two-fold and XRCC1 is upregulated by more than two-fold across all cancer types (Fig. 2B). Altogether, this 
analysis suggests that the increase in DPCs in cancer might be caused by a lack of ALDH2 expression. This 
deficiency, however, coincides with a higher expression of XRCC1, which is required for the BER pathway. 
 
3.3 Low ALDH2 levels predict a poor 5-year overall survival rate for lung and liver cancers but not for 
oesophagus cancer 
To understand further the relevance of the interplay between XRCC1 and ALDH2 expression in cancer, we 
investigated whether the profile we observed in most cancers (i.e., low ALDH2 and high XRCC1 mRNA levels, 
Fig. 2) affects patient prognosis. To do so, we extracted provisional mRNA data from “The Cancer Genome Atlas” 
(TCGA) through the database cBioPortal [22, 23]. We selected data for lung (522 samples, Table S2) and liver 
(422 samples, Table S3) cancers in which the differences between ALDH2 and XRCC1 mRNA levels are 
pronounced (Fig. 3A and 4A) and compared these data to oesophageal cancer (186 samples, Table S4) in which 
XRCC1 and ALDH2 mRNA levels are very close (Fig. 5A). Looking at the overall survival rate at 5 years, we 
found that the XRCC1 mRNA level itself has no prognostic value in any of these cancers (Fig. 3B, 4B and 5B). 
On the contrary, we found that low ALDH2 mRNA levels, defined by separating value at the median, strongly 
predict a worse prognosis in lung and liver cancer (Fig. 3C and 4C). Interestingly, we found that the ALDH2 
mRNA levels have no prognosis value in oesophageal cancer (Fig. 5C). Therefore, although XRCC1 mRNA 
levels alone have no prognostic value, low ALDH2 levels show a worse prognosis at 5 years, only in cancers 
showing a marked difference between ALDH2 and XRCC1 expression. 
 
3.4 XRCC1 levels or XRCC1/ALDH2 ratios further stratify the effect of low ALDH2 expression on 5-year 
overall survival 
In liver cancer patients, we observed a significant impact of ALDH2 mRNA expression on the overall survival 
rate, whereas the XRCC1 mRNA level itself had no predictive value (Fig. 4). Nevertheless, we stratified patients 
into two groups, low and high XRCC1 mRNA expression, and investigated whether this stratification improves 
the significance of ALDH2 mRNA expression on the prognosis. Strikingly, we found that the ALDH2 mRNA 
level has no prognostic value in the low XRCC1 mRNA expression group (Fig. 6A), whereas, in the high XRCC1 
mRNA expression group, low ALDH2 mRNA expression was found to predict a very poor prognosis (Fig. 6B). 
Interestingly, we found that the XRCC1 mRNA levels are higher in the low ALDH2 mRNA samples (Fig. 6C) 
and that the ADLH2 mRNA levels are lower in the high XRCC1 mRNA group (Fig. 6D), confirming the above 
observed interplay between XRCC1 and ALDH2 expression (Fig. 1). In order to support the connection with the 
in vitro data of Fig. 1, we also used the APE1 and TDP1 mRNA levels to stratify ALDH2 expression and prognosis 
in liver cancer (Fig. S1). Interestingly, we found that APE1, whose depletion does not induce SSBs in their pure 
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form [25], does not stratify the ALDH2 prognosis value (Fig. S1A and S1B). However, TDP1, whose depletion 
does mimic XRCC1 loss (Figure 1F), was found to stratify the ALDH2 prognosis value in a similar fashion to 
XRCC1, although less powerfully (Figs. S1C and S1D). The POLβ levels did not show any prognostic value in 
liver carcinomas (data not shown). Next, we investigated whether the XRCC1 mRNA/ALDH2 mRNA expression 
ratio could also be used as a prediction factor. We found that the XRCC1 mRNA/ALDH2 mRNA ratio is 
significantly better at predicting the 5-year overall survival rate for both lung (Fig. 7A, compare to 3C) and liver 
(Fig. 7B, compare to 4C) cancers than ALDH2 levels alone. In oesophageal cancer, where the XRCC1 and 
ALDH2 mRNA levels show no difference (Fig. 5A), the XRCC1 mRNA/ALDH2 mRNA ratio shows no 
improvement in predicting the overall survival rate (Fig. 7C, compare to 5C). We thus concluded that XRCC1 
mRNA levels along with ALDH2 mRNA levels may be used for stratification in order to predict the 5-year overall 
survival rate in liver and lung cancer patients and to refine their treatment strategy. 
 
3.5 Cancer-derived cell lines with low ALDH2 mRNA levels are sensitive to Sp1 inhibitor Mithramycin A 
We showed that XRCC1 and ALDH2 mRNA levels are related and that a high XRCC1 mRNA/low ALDH2 
mRNA ratio seems to be accompanied by tumour aggressiveness in patients. We then wondered whether 
destabilising this balance could have a deleterious effect on cancer cell survival. To do so, we selected two cancer-
derived cell lines, i.e., H1299, a lung cancer cell line with a low ALDH2 expression and JHH4, a liver cancer cell 
line with a high ALDH2 expression (Fig. 8A). We then proceeded to knock down XRCC1 mRNA expression, 
ALDH2 expression, or both, and investigated the cellular survival using a clonogenic assay. We found that H1299 
cells (ALDH2 low), do not tolerate decreases in both XRCC1 and ALDH2 proteins (Figs. 8B and 8D, last column), 
whereas JHH4 cells (ALDH2 high), cope better after a double knockdown of XRCC1 and ALDH2 (Figs. 8C and 
8E, last column) most probably because they do not completely lose ALDH2 expression after knockdown (Fig. 
8C). Interestingly, we found that ALDH2 knockdown alone promotes higher survival rates for both the H1299 
(Fig. 8D, column 3) and JHH4 (Fig. 8E, column 3) cell lines, supporting our observation that lower ALDH2 levels 
are advantageous for cancer cells (Fig. 2). We also found that single knockdown of XRCC1 does not reduce the 
survival of H1299 cells (Fig. 8D, second column) even if their level of ALDH2 is already low. We believe that 
this may be due to there being some BER activity remaining as a result of incomplete siRNA knockdown of 
XRCC1 gene expression [25]. We thus hypothesise that H1299 cells may be sensitised by a global shutting down 
of the BER pathway. We have recently uncovered that inhibition of the Sp1 transcription factor decreases the 
expression of the BER protein APE1 [25], as well as other members of this pathway [30]. We, therefore, set out 
to investigate the survival of H1299 and JHH4 cells after treatment with the Sp1 inhibitor Mithramycin A. We 
found that H1299 cells are extremely sensitive to very low doses of Mithramycin A, whereas JHH4 cells are 
resistant (Fig. 9A). We also confirmed a decreased expression of XRCC1 and APE1 in JHH4 (Fig. 9B) and H1299 
(Fig. 9C) cells after Sp1 inhibition by qRT-PCR. Because Sp1 regulates the whole BER pathway, Sp1 inhibition 
seems more potent in killing H1299 cells than depletion of XRCC1 alone. These data represent a proof of principle 
that, although low expression of ALDH2 gives cancer cells some growth advantage (Figs. 8D and 8E), they may 
still be dependent on an efficient BER pathway (Fig. 9A). In conclusion, we found that several types of cancer 
show a profile with a lower ALDH2 and a higher XRCC1 expression that is linked to a poor prognosis. Cancer 
cells with this profile could potentially be targeted by using BER enzyme inhibitors or by shutting down the 
pathway through BER gene expression inhibition. 
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4 Discussion  
 
Metabolic changes are a cornerstone of cancer development [31, 32]. Recent scientific advances in the 
understanding of cancer metabolism have shown the importance of defining the pathways that may limit cancer 
progression with the hope of designing reliable clinical strategies with benefits for the patient [32]. In this context, 
the pathways to be targeted must represent unique avenues taken by cancer cells to boost their proliferation and 
survival. By using these particular metabolic reactions, cancer cells leave traces or clues in the form of specific 
waste products that can be used to trace new metabolic pathways used by them [33]. BER is one of the first DNA 
repair pathways deregulated during cancer progression [25]. Here, we used XRCC1 levels as a readout for BER 
efficiency. This is because XRCC1 depletion is a model known for the purity of the type of lesion it causes, 
compared to APE1 depletion, and for the robust BER deficiency it induces, compared to POLβ depletion [17, 25, 
26]. We have previously shown that the loss of XRCC1 triggers metabolic changes resembling those found in 
many cancers [17, 34]. Here, we hypothesised that alterations in aldehyde metabolism could be part of these 
changes. Recently, aldehydes such as AcAl, methylglyoxal and formaldehyde have generated significant interest 
for their role as waste products of cancer metabolism [33, 35-37]. Interestingly, aldehyde production, when linked 
to beneficial metabolic pathways for cancer, acts as a double-edged sword associated with high genotoxicity [33, 
35]. Cancer cells rely on detoxification enzymes such as ALDH2 that can neutralise aldehydes and keep a 
semblance of metabolic equilibrium [5, 29, 38]. Nevertheless, cancer cells frequently exhibit an excess of 
aldehydes and, therefore, a high occurrence of aldehyde-related DPCs and genetic instability [9, 28, 37]. 
Surprisingly, we observed in this study by using bioinformatics analysis that most cancers, especially lung and 
liver carcinomas, gamble with lowering their expression of ALDH2 along with overexpressing XRCC1. This 
observation correlates with the growing body of evidence indicating a high occurrence of DPCs and their link to 
genetic instability in cancer [27, 28]. Interestingly, DPC accumulation in the liver is particularly oncogenic as it 
has been found that patients lacking the fundamental DNA-protein crosslink repair metalloprotease 
SPRTN/DVC1 develop very early onset aggressive hepatocellular carcinoma [39]. Indeed, we show that inhibition 
of ALDH2 increases the occurrence of DPCs and that low expression of ALDH2 is associated with a poor 
prognosis for liver cancer patients. Surprisingly, despite the existence of different ALDH isoforms, we found that 
only ALDH2 expression has an impact on liver cancer (data not shown). This would suggest a fundamental 
function of ALDH2 in aldehyde detoxification, superior to any other ALDHs. 
Several non-exclusive hypotheses can be made for a putative role of BER in the control of aldehyde-
related damage. Firstly, our data support the idea that BER is involved directly in the repair of aldehyde-related 
damage. Aldehydes attack DNA bases and these alterations can be repaired by BER [40]. In addition, it has been 
proposed that BER may be involved in the repair of DNA inter-strand crosslinks that can be also caused by 
aldehydes [41, 42]. Finally, although there are very little data linking BER to the repair of DPCs, it is interesting 
to note that XRCC1 is involved in the removal and repair of lesions caused by trapped TOP1, and so is TDP1 
[43]. If the TOP1 removal mechanism shares any similarity to DPC repair, this could potentially place BER 
downstream of SPRTN/DVC1 after the removal of the crosslinked protein. Altogether, this could mean that the 
BER pathway may be involved in the repair of aldehyde-related DPCs and this, in turn, could explain why low 
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ALDH2 expressing cancer cells have increased BER levels. Secondly, our data could be interpreted by using an 
alternative scenario, seeing loss of BER as a cause of aldehyde-related toxicity. We have previously shown that 
the loss of BER triggers metabolic changes, notably by increasing the activity of the one-carbon cycle [17]. More 
recently, it has been shown that endogenously produced formaldehyde plays a major part in the one-carbon cycle 
[37]. If BER-deficient cells increase the activity of this cycle, it is reasonable to suggest that this would, in turn, 
increase the concentration of formaldehyde in the cell as both a waste product and a reaction intermediate. 
Interestingly, we previously found that BER-deficient cells exhibit increased levels of the anti-oxidant GSH [20]. 
It is known that GSH can be used as an alternative to detoxify aldehydes [2]. Therefore, we propose that BER-
deficient cells increase ALDH2 expression in order to prevent aldehyde-induced DNA damage. This would mean 
that low ALDH2 expressing cancer cells are at high risk of aldehyde overload if BER levels are not high enough. 
Thirdly, we could envisage that BER-deficiency, by creating numerous SSBs, some of which may contain 
aldehydes at the end of the strand break [43], can easily cause DPCs [26]. This hypothesis is reinforced by the 
fact that the two models used in this study, XRCC1 and TDP1 depletion, have in common a very substantial 
accumulation of SSBs. Finally, whatever the role of BER, knowing that any or all these hypotheses could be 
correct, we propose as proof of principle that cells may not survive by losing both BER and ALDH2 activities. 
By inhibiting Sp1, one of the main regulators of BER protein expression [25], we observed a higher sensitivity 
for BER loss in cells expressing low levels of ALDH2. Although Mithramycin A is quite toxic in vivo [44] and 
cannot be used to treat patients directly, the development of less toxic Mithramycin A derivatives or the use of 
other BER inhibitors [45-47] may open up a new avenues to target specific metabolic defects employed by some 
cancer cells. 
In conclusion, we have discovered a previously unknown interconnection between the BER pathway and 
aldehyde detoxification. We demonstrated the importance of this relationship in the prognosis of liver and lung 
cancer and suggest that these observations may pave a new way towards targeting cancer metabolism. 
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Figure Legends 
 
Figure 1. XRCC1 depletion causes an increased expression of ALDH2 and more DNA-protein crosslinks 
(A) qRT-PCR analysis of ALDH2 transcript levels in NBE1 cells after 72h of XRCC1 knock down (KD). (B) 
Representative Western blot analysis of ALDH2 and XRCC1 levels in NBE1 cells after 72h of XRCC1 KD. (C) 
Representative immunofluorescence analysis of ALDH2 in NBE1 cells after 72h of XRCC1 KD. (D) qRT-PCR 
analysis of ALDH2 and XRCC1 transcript levels in TIG1 cells after 72h of XRCC1 KD. (E) qRT-PCR analysis 
of ALDH2 and XRCC1 transcript levels in WI38 cells after 72h of XRCC1 KD. (F) qRT-PCR analysis of ALDH2 
and TDP1 transcript levels in TIG1 cells after 72h of TDP1 KD. qRT-PCR reference genes are B2M and GAPDH 
for A, D and E, and TBP and GAPDH for F. (G) Left panel, representative silver staining analysis of protein 
crosslinked onto DNA in NBE1 cell extracts after 72h of XRCC1 KD or 24h of disulfiram treatment (10 µM). 
Right panel, densitometric quantification of the data. Data are expressed as mean ± SD from at least three 
independent experiments * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Figure 2. XRCC1 and ALDH2 mRNA levels mirror each other in most cancer types 
(A) Boxplot summarising the fold changes in mRNA levels for ALDH2 (blue) and XRCC1 (red) depending on 
the cancer type. (B) Boxplot representing the overall variation in XRCC1 and ALDH2 levels in all cancer types. 
A list of the studies used and the associated mRNA fold changes can be found in Table S1. 
 
Figure 3. Low ALDH2 expression predicts a poor prognosis in lung cancer 
(A) Boxplot representing the overall variation in XRCC1 and ALDH2 expression levels in lung cancers 
(Oncomine). (B) Kaplan-Meier analysis of the 5-year overall survival of lung cancer patients (provisional TCGA) 
stratified for XRCC1 mRNA levels (cut at the median). (C) Kaplan-Meier analysis of the 5-year overall survival 
of lung cancer patients (provisional TCGA) stratified for ALDH2 mRNA levels (cut at the median). 
 
Figure 4.  Low ALDH2 expression predicts a poor prognosis in liver cancer 
(A) Boxplot representing the overall variation in XRCC1 and ALDH2 levels in liver cancers (Oncomine). (B) 
Kaplan-Meier analysis of the 5-year overall survival of liver cancer patients (provisional TCGA) stratified for 
XRCC1 mRNA levels (cut at the median). (C) Kaplan-Meier analysis of the 5-year overall survival of liver cancer 
patients (provisional TCGA) stratified for ALDH2 mRNA levels (cut at the median). 
 
Figure 5. ALDH2 and XRCC1 expression have no predictive value in oesophagus cancer 
(A) Boxplot representing the overall variation in XRCC1 and ALDH2 levels in oesophageal cancers (Oncomine). 
(B) Kaplan-Meier analysis of the 5-year overall survival of oesophageal cancer patients (provisional TCGA) 
stratified for XRCC1 mRNA levels (cut at the median). (C) Kaplan-Meier analysis of the 5-year overall survival 
of oesophagus cancer patients (provisional TCGA) stratified for ALDH2 mRNA levels (cut at the median). 
 
Figure 6. XRCC1 levels increase the predictive value of ALDH2 expression in liver cancer 
(A) Kaplan-Meier analysis of the 5-year overall survival of liver cancer patients (provisional TCGA) pre-stratified 
for low XRCC1 mRNA levels and stratified for ALDH2 expression (cut at the median). (B) Kaplan-Meier analysis 
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of the 5-year overall survival of liver cancer patients (provisional TCGA) pre-stratified for high XRCC1 mRNA 
levels and stratified for ALDH2 expression (cut at the median). (C) Boxplot representing the overall variation in 
XRCC1 mRNA levels in liver cancers (provisional TCGA) depending on ALDH2 expression group (cut at the 
median). (D) Boxplot representing the overall variation in ALDH2 mRNA levels in liver cancers (provisional 
TCGA) depending on XRCC1 expression group (cut at the median). 
 
Figure 7. XRCC1/ALDH2 mRNA level ratio has an increased predictive value compared to that of ALDH2 
expression alone in lung and liver cancer 
(A) Kaplan-Meier analysis of the 5-year overall survival of lung cancer patients (provisional TCGA) stratified for 
a XRCC1/ALDH2 mRNA levels ratio (cut at the median). (B) Kaplan-Meier analysis of the 5-year overall survival 
of liver cancer patients (provisional TCGA) stratified for a XRCC1/ALDH2 mRNA levels ratio (cut at the 
median). (C) Kaplan-Meier analysis of the 5-year overall survival of oesophageal cancer patients (provisional 
TCGA) stratified for a XRCC1/ALDH2 mRNA levels ratio (cut at the median). 
 
Figure 8. Co-depletion of XRCC1 and ALDH2 sensitises low ALDH2-expressing cancer cells 
(A) Representative Western blot analysis of ALDH2 and XRCC1 levels in H1299 and JHH4 cells. Densitometric 
quantifications of the data are presented below. (B) Representative Western blot analysis of ALDH2 and XRCC1 
levels in H1299 cells after 72h of XRCC1 and/or ALDH2 knock down (KD). (C) Representative Western blot 
analysis of ALDH2 and XRCC1 levels in JHH4 cells after 72h of XRCC1 and/or ALDH2 KD. (D) Clonogenic 
analysis performed in H1299 cells after 72h of XRCC1 and/or ALDH2 KD. (E) Clonogenic analysis performed 
in JHH4 cells after 72h of XRCC1 and/or ALDH2 KD. Data are expressed as mean ± SD from at least three 
independent experiments * p < 0.05; N.S.: non-significant. 
 
Figure 9. Sp1 inhibitor Mithramycin A kills low ALDH2 expressing cancer cells 
(A) Clonogenic analysis performed in H1299 and JHH4 cells after two subsequent 24 h treatments (total 48 h) 
with Mithramycin A. (B) qRT-PCR analysis of XRCC1 and APE1 mRNA levels in JHH4 cells after treatment 
with 50 nM or 500 nM Mithramycin A for 24 h. (C) qRT-PCR analysis of XRCC1 and APE1 mRNA levels in 
H1299 cells after treatment with 50 nM or 500 nM Mithramycin A for 24 h. qRT-PCR reference genes are B2M 
and GAPDH. Data are expressed as mean ± SD from at least three independent experiments. *** p < 0.001. 










